SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-21-007757
Filing Date
2021-07-08
Accepted
2021-07-08 16:15:31
Documents
4
Period of Report
2021-07-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT vtgn8k_07062021.htm 8-K 32025
2 INDEMNIFICATION AGREEMENT, DATED JULY 6, 2021, BY AND BETWEEN VISTAGEN THERAPEUT ex10-1.htm EX-10.1 59525
3 PRESS RELEASE ISSUED BYVISTAGEN THERAPEUTICS, INC., DATED JULY 7, 2021 ex99-1.htm EX-99.1 13435
4 IMAGE vistagen.jpg GRAPHIC 4408
  Complete submission text file 0001654954-21-007757.txt   112506
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 211080339
SIC: 2834 Pharmaceutical Preparations